CLINICAL_TRIALS trial_result · 2025-05-08

Clinical Trial Update: Add-on Dupilumab for AFRS as Postoperative Therapy (ADAPT) [Phase 3]

Phase 3 trial ADAPT evaluating add-on dupilumab for allergic fungal rhinosinusitis after surgery was terminated, with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Emory University | Conditions: Allergic Fungal Rhinosinusitis | Phase 3 | Status: TERMINATED | Results posted: 2025-05-08